Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer

Published:2015-04 Issue:4 Volume:10 Page:665-672
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Cappuzzo Federico,Finocchiaro Giovanna,Grossi Francesco,Bidoli Paolo,Favaretto Adolfo,Marchetti Antonio,Valente Maria Luisa,Cseh Agnieszka,Clementi Laura,Massey Dan,Santoro Armando

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer;Genome Medicine;2024-04-11

2. Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial;European Journal of Cancer;2023-07

3. Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice;Frontiers in Pharmacology;2023-04-07

4. Single cell lineage tracing reveals clonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer;2023-04-06

5. Analysis of Copy Number Variations in Solid Tumors Using a Next Generation Sequencing Custom Panel;Journal of Molecular Pathology;2021-05-21